TEVA Company Profile

What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?

TEVA has seven hundred and thirty-eight approved drugs.

There are one hundred US patents protecting TEVA drugs. There are fifty-three tentative approvals on TEVA drugs.

There are nine hundred and twenty-two patent family members on TEVA drugs in forty-nine countries and one thousand and seventy-six supplementary protection certificates in eighteen countries.

Summary for TEVA

International Patents:	922
US Patents:	100
Tradenames:	510
Ingredients:	445
NDAs:	738
Patent Litigation for TEVA:	See patent lawsuits for TEVA
PTAB Cases with TEVA as petitioner:	See PTAB cases with TEVA as petitioner

Drugs and US Patents for TEVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	077488-005	Apr 29, 2013		DISCN	No	No
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-005	Jul 12, 2019		RX	Yes	No	9,731,087*PED				Y
Teva	NORTRIPTYLINE HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	074132-002	Mar 27, 1995	AB	RX	No	No
Teva	VENLAFAXINE HYDROCHLORIDE	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	076565-003	Jun 28, 2010	AB	RX	No	No
Teva	ACYCLOVIR	acyclovir	CAPSULE;ORAL	074578-001	Apr 22, 1997	AB	RX	No	No

Expired US Patents for TEVA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharm	AIRDUO DIGIHALER	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-006	Jul 12, 2019	6,718,972
Teva Branded Pharm	PROAIR HFA	albuterol sulfate	AEROSOL, METERED;INHALATION	021457-001	Oct 29, 2004	5,695,743
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-001	Mar 23, 2012	5,776,432
Teva Womens	ADDERALL 30	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-010	May 12, 1997	6,384,020*PED
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-003	Jan 27, 2017	6,701,917

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	for Injection	100 mcg/vial and 500 mcg/vial		2015-04-14
	Tablets	1 mg/0.02 mg and 75 mg		2006-04-17
	Delayed-release Tablets	20 mg		2015-06-03
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	for Injection	200 mcg/vial		2015-05-01
	for Injection	3.5 mg/vial		2016-10-26
	Tablets	0.5 mg and 1 mg		2010-05-17
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10

Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for TEVA Drugs

Country	Patent Number	Estimated Expiration
Japan	2010508275
Hungary	E038158
Canada	2887315
Spain	2529358
Spain	2334774

Supplementary Protection Certificates for TEVA Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0817775	SPC/GB06/008	United Kingdom		PRODUCT NAME: ERLOTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OR POLYMORPH THEREOF, IN PARTICULAR THE HYDROCHLORIDE SALT; REGISTERED: CH 5726601 20050321; CH 5726602 20050321; CH 5726603 20050321; UK EU/1/05/311/001 20050919; UK EU/1/05/311/002 20050919; UK EU/1/05/311/003 20050919
2340828	LUC00195	Luxembourg		PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123
0316704	2001C/021	Belgium		PRODUCT NAME: CAPECITABINE, NATL REGISTRATION NO/DATE: EU/1/00/163/001 20010205; FIRST REGISTRATION: CH 54657 19980610
0613371	SPC/GB02/033	United Kingdom		PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515
2105135	1590004-6	Sweden		PRODUCT NAME: POMALIDOMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES, HYDRATES OR STEREOISOMERS THEREOF; REG. NO/DATE: EU/1/13/850 20130808

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm
• Teva Pharms